Chief Executive Officer
CurrentBioProtonics has developed and patented a new technology platform (i.e. methods and software) called Magnetic Resonance Histopathology (MRH) that works on existing Magnetic Resonance Imaging (MRI) devices. For the first time, MRH provides meaningful MR diagnostic imaging resolution on tissue at the micro-level (sub 1mm). Also, very important for broad commercialization, MRH adds less than 1 minute to current MRI scan time and corrects for patient movement during scans. MRH potentially will lead to a safer, less invasive, less costly alternative for many biopsies routinely performed today of which the majority are negative. This advancement will allow for earlier detection of many diseases and cancers and enable more accurate therapies sooner in the disease cycle to improve patient outcomes and lower medical costs. Eventually MRH could be part of every MRI scan.